Spain Imported More Medical Cannabis Than It Exported for the First Time

Spain’s H1 2026 trade data show a 7,425 kg import surplus

Spain imported 25,730 kg of medical cannabis in the first six months of 2026 and exported 18,305 kg, according to newly published transparency data from the Spanish medicines agency, AEMPS. The result is a 7,425 kg import surplus.

That is the first reported period in which Spanish imports have exceeded exports. It matters because Spain has long been framed as a cultivation and export base for European medical cannabis. The new figures show a more complicated role taking shape: Spain is also receiving large volumes of cannabis material from abroad, processing or preparing it within its regulated supply chain, and then moving some of that material onward.

Portugal was the largest identified supplier in the period, sending 11,386 kg to Spain. That was about 44% of all Spanish medical-cannabis imports in January through June. The scale makes the Iberian connection central to the numbers, not a marginal feature of them.

The figures do not show that Spanish patients are suddenly receiving a broader range of cannabis treatments. Cross-border trade volume and domestic access are different measures. Material can be imported under controlled permissions for manufacturing, quality work, research, preparation or export without becoming a routinely available treatment for patients in Spain.

That distinction is the real news beneath the trade balance. Spain’s medical-cannabis economy is becoming more visibly integrated into European industrial supply chains, while its patient-facing route remains narrow, hospital-centred and dependent on a separate product-registration system.

Portugal’s 11,386 kg points to a processing chain, not a retail market

The import total needs to be read as a supply-chain figure. Medical cannabis does not move across borders as an ordinary consumer product. Cannabis material is controlled, and licensed businesses need the relevant authorisations to cultivate, import, export, manufacture, possess and handle it. A shipment may involve dried flower, extracts or other material intended for a regulated next step rather than immediate use by a patient.

For Spain, that next step may include processing the material into a standardised preparation, carrying out quality-control work, preparing an ingredient for a compounded formula, or supplying another authorised destination. A compounded formula is a medicine prepared by a pharmacy for an individual patient under a prescription, rather than a mass-market packaged product sold from a normal retail shelf.

This is why a larger import figure can sit alongside a still-restricted domestic medical system. The goods may be travelling through Spain because its licensed facilities, professional expertise or location serve a wider European production network. The trade data record lawful movement of regulated cannabis material. They do not identify a patient population, a prescription count or a retail sales total.

Portugal’s 11,386 kg contribution illustrates the division of labour developing across the peninsula. Portugal has built a substantial licensed cultivation and export sector, with products and raw material moving to medical markets and manufacturing partners elsewhere in Europe. Spain, meanwhile, has licensed cultivation, handling and manufacturing capacity of its own, but is now also a significant recipient of imported supply.

The H1 result does not establish why every kilogram entered Spain or what proportion was ultimately processed, retained, re-exported or used for another authorised purpose. It also does not prove that imports will exceed exports over the full year. A six-month period can be shaped by shipment timing, inventory purchases, customer contracts and the cadence of regulatory approvals.

But the direction is still material. Imports of 25,730 kg are not a small balancing item against 18,305 kg of exports. The 7,425 kg gap is large enough to challenge the simple view of Spain as a one-way exporter of medical cannabis to other European countries.

It also points to a practical reality for operators. Cultivation is only one piece of the market. Businesses with compliant import procedures, controlled storage, extraction or formulation capacity, laboratory systems and documented quality standards can become commercially important even when they do not grow the crop. The value of the chain can move toward the places able to receive, transform and release material into the next regulated stage.

That is not a guarantee of profitable processing. Cross-border cannabis remains paperwork-heavy and operationally demanding. Each stage can require security controls, traceability, batch testing, qualified personnel and approvals from more than one authority. A processing hub needs contracts and predictable demand, not only permission to handle cannabis. Still, the import surplus shows that Spain is already being used for more than domestic cultivation and outbound shipments.

Hospital pharmacies, registered preparations and a much smaller route to patients

Spain’s domestic framework is deliberately more limited than the trade numbers may imply. The official system centres on standardised cannabis preparations registered with AEMPS. The public register is not a broad catalogue of retail cannabis goods. It identifies the preparations that can be used in compounded cannabis formulas within the regulated medical pathway.

Manufacturers seeking to place a standardised preparation on that route must apply to AEMPS. The application process is intended to establish the preparation’s specifications and consistency, including the cannabinoid profile and the quality information needed for a pharmacy to make a controlled formula. This is a gate between industrial supply and clinical use.

Spain’s Royal Decree framework confines prescribing to specialist physicians and makes the hospital setting central to care. The preparations are made through hospital pharmacy services and dispensed through hospital pharmacies. That excludes ordinary cannabis retail from the system. It also excludes routine dispensing through community pharmacies, which are the neighbourhood pharmacies used for most standard prescriptions.

Eligibility is constrained by more than where a patient collects a preparation. The route is designed for specific clinical circumstances: spasticity associated with multiple sclerosis; severe epilepsy that has not responded to standard treatment; nausea and vomiting caused by chemotherapy; and chronic refractory pain, meaning pain that has not responded adequately to established treatment. The framework also allows AEMPS to add further clinical uses where the evidence supports doing so.

For the listed conditions, cannabis preparations are not positioned as a first-line option. The system is for patients whose conventional treatment has not provided sufficient results, or for whom established options are not appropriate. Specialist clinical judgment therefore remains a material condition of access alongside the diagnosis itself.

The excluded groups are clear in practical terms. A person without one of the covered clinical situations does not gain access because cannabis has entered Spain in larger quantities. A patient whose condition is covered but who has not gone through the specialist and hospital pathway is not on the regulated route. A general retail consumer cannot use the medical framework. Nor can a community pharmacy treat an imported batch as a product it may simply stock and sell.

Products are constrained too. Cannabis material imported into Spain is not automatically a registered standardised preparation. And a cannabis preparation not entered in the AEMPS register cannot be used through the ordinary compounded-formula route created by the framework. Registration does not turn cannabis into a general consumer medicine; it makes a particular, defined preparation eligible for controlled use by the authorised medical and pharmacy services.

These conditions explain why trade throughput should not be mistaken for liberalisation. A large shipment may be commercially significant to a cultivator, importer, laboratory or manufacturer. It can still be irrelevant to a patient unless it reaches the registered-product system, is selected by an authorised clinician for an eligible medical circumstance, is prepared through a hospital pharmacy and is dispensed through that hospital route.

The distinction also places pressure on the industry’s public claims. Operators can accurately describe a growing Iberian and European supply chain without suggesting that the Spanish medical market has become a broad prescription market. The available domestic channel remains structured around selected conditions, specialist oversight and hospital pharmacy practice.

For healthcare institutions, that narrowness has consequences. Hospitals and their pharmacy services, rather than high-street dispensaries or general pharmacies, carry the operational burden of patient access. They need to manage prescribing protocols, preparation standards, supply reliability and follow-up within a controlled setting. Whether enough hospitals, clinicians and registered preparations will participate to create meaningful national availability remains unresolved.

Spain’s opportunity is industrial, while patient access still depends on execution

The import surplus changes the questions facing cannabis businesses. For Spanish cultivators, it is evidence that domestic supply will not automatically have the field to itself. Imported material, especially from nearby Portugal, can compete for processing capacity and downstream contracts. The relevant competitive advantage may be more than cultivation cost. It may include consistency, documentation, cannabinoid specifications, delivery reliability and the ability to meet a buyer’s required quality standard batch after batch.

For Portuguese producers, the data show that Spain is not only a neighbouring jurisdiction with its own cultivation permits. It is a meaningful outlet and potentially a manufacturing partner. The 11,386 kg sent from Portugal in six months indicates industrial demand at a scale that can support cross-border relationships. It does not, however, reveal the commercial terms, margins or durability of those arrangements.

For processors and pharmaceutical-service businesses, the development may be more consequential than for consumer-facing brands. Spain’s rules place value on standardisation, controlled preparation and hospital-pharmacy compatibility. Companies able to work inside that system may find opportunities in formulation, testing, release procedures, import administration and supply to authorised pharmacy channels.

Those opportunities remain bounded by the small number of routes from industrial material to Spanish patients. The AEMPS register and the associated manufacturer application process are central because they determine which preparations can support compounded formulas. A growing volume of cannabis moving through warehouses or facilities does not by itself expand that list. Nor does it ensure that hospital prescribers will adopt the products or that hospital pharmacy services will build regular capacity around them.

For investors and policy watchers, the new trade pattern is a warning against using a single number as a measure of market maturity. Export volume can overstate domestic commercial demand. Import volume can overstate patient access. Even an import surplus can reflect a short-term inventory build or production timetable rather than a settled new equilibrium.

What the numbers do establish is that Spain has become important as a two-way medical-cannabis jurisdiction. The country is receiving enough product from abroad to overturn its former export-only image, and Portugal has become the dominant identified source in the first-half data. This is evidence of a regional supply chain gaining substance.

The harder test is still ahead. A true domestic medical market requires more than licensed movement of cannabis across a border. It requires registered preparations, specialists willing and able to prescribe within the permitted indications, hospital pharmacy capacity and a system that turns legal eligibility into practical treatment access.

Spain now appears positioned to be a processing and supply-chain hub whether or not that domestic pathway expands quickly. That is a durable industrial possibility, but it is not the same achievement as building a widely usable patient system. The first will be measured in kilograms moving through controlled facilities. The second will be measured in whether the narrow hospital route can function consistently for the patients it is meant to serve.